Catalyst

Slingshot members are tracking this event:

Topline Results Released From Gilead's (GILD) Phase 2 ATLAS Study of cilofexor 30 mg, firsocostat 20 mg and selonsertib 18 mg in Patients With Bridging Fibrosis and Compensated Cirrhosis Due to NASH

Source Link:
https://www.gilead.com/news-and-press/press-room/press-releases/2019/12/gilead-announces-topline-results-from-phase-2-atlas-study-in-patients-with-bridging-fibrosis-f3-and-compensated-cirrhosis-f4-due-to-nonalcoholic-s

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
GILD
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Clinical Data Study Primary Endpoint Was Not Met; Improvement in Multiple Measures of Fibrosis and Liver Injury Was Observed with Investigational Firsocostat and Cilofexor
https://www.gilead.c...
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Dec 16, 2019
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2, Atlas, Fibrosis, Bridging Fibrosis, Compensated Cirrhosis, Nash, Cilofexor, Firsocostat, Selonsertib
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.